Genomes and Genes
angiotensin ii type 1 receptor blockers
Summary: Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
Publications322 found, 100 shown here
- Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetesHermann Haller
Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
N Engl J Med 364:907-17. 2011..We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria...
- Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trialsIlke Sipahi
Harrington McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
Lancet Oncol 11:627-36. 2010..We assessed whether ARBs affect cancer occurrence with a meta-analysis of randomised controlled trials of these drugs...
- Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonismJennifer P Habashi
Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Science 332:361-5. 2011..These data highlight the protective nature of AT2 signaling and potentially inform the choice of therapies in MFS and related disorders...
- Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activityStephen C Benson
Department of Biological Sciences, California State University, Hayward, USA
Hypertension 43:993-1002. 2004....
- Irbesartan in patients with heart failure and preserved ejection fractionBarry M Massie
University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA
N Engl J Med 359:2456-67. 2008..Therefore, we studied the effects of irbesartan in patients with this syndrome...
- Feasibility of treating prehypertension with an angiotensin-receptor blockerStevo Julius
University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
N Engl J Med 354:1685-97. 2006..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALDick de Zeeuw
Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
Kidney Int 65:2309-20. 2004....
- Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosisKen ichiro Okada
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Circulation 110:705-12. 2004..The ER responds to stress by upregulating ER chaperones, but prolonged and/or excess ER stress leads to apoptosis. However, the potential role of ER stress in pathophysiological hearts remains unclear...
- The podocyte's response to injury: role in proteinuria and glomerulosclerosisS J Shankland
Department of Medicine, Division of Nephrology, University of Washington, Seattle, Washington 98195, USA
Kidney Int 69:2131-47. 2006..It is the hope that by delineating the events following injury to podocytes, therapies might be developed to reduce the burden of proteinuric renal diseases...
- Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activityMichael Schupp
Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Campus Charite Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
Circulation 109:2054-7. 2004..The peroxisome proliferator-activated receptor-gamma (PPARgamma) is the central regulator of insulin and glucose metabolism improving insulin sensitivity. We investigated the regulation of PPARgamma function by ARBs...
- Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patientsYoshio Matsui
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311 1 Yakushiji, Shimotsuke, Tochigi, Japan
Hypertension 54:716-23. 2009..0 mg) and hydrochlorothiazide (12.5 mg), despite the lack of a significant difference in brachial systolic BP reduction between the 2 treatments...
- Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trialMarvin A Konstam
Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA
Lancet 374:1840-8. 2009..We compared the effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure...
- Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophyScott D Solomon
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 119:530-7. 2009..We compared the effect of aliskiren, the first orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combination on the reduction of LV mass in hypertensive patients...
- Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST StudyIkuo Saito
Keio University Health Center, Kanagawa, Japan
Hypertens Res 36:177-82. 2013..The HONEST Study is expected to provide evidence showing the relationship between baseline and on-treatment CBP and HBP levels (both first and second measurements) and CV events...
- Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled studyE Imai
Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa Ku, Nagoya, Aichi 466 8550, Japan
Diabetologia 54:2978-86. 2011..The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a contemporary regimen including an angiotensin converting enzyme inhibitor (ACEI)...
- Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndromeJennifer P Habashi
Howard Hughes Medical Institute and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Science 312:117-21. 2006....
- Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyDick de Zeeuw
Department of Clinical Pharmacology, Groningen University Medical Center, Ant Deusinglaan 1, 9713 AV Groningen, Netherlands
Circulation 110:921-7. 2004..Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention...
- Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) studySrikanth Sola
Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA
Circulation 111:343-8. 2005..We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, to affect endothelial function and inflammation in patients with the metabolic syndrome...
- Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal diseaseRegina Kunz
Basel Institute for Clinical Epidemiology and Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland
Ann Intern Med 148:30-48. 2008..Reports suggest that angiotensin-receptor blockers (ARBs) reduce proteinuria, but results are variable. The relative effect of ARBs and angiotensin-converting enzyme (ACE) inhibitors, and their combined administration, remains uncertain...
- Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertensionDavid B Matchar
Duke Center for Clinical Health Policy Research, Duke Clinical Research Institute, Duke University, and Durham U S Department of Veterans Affairs Medical Center, Durham, North Carolina 27705, USA
Ann Intern Med 148:16-29. 2008..The relative effectiveness of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for lowering blood pressure is unknown...
- Telmisartan, ramipril, or both in patients at high risk for vascular eventsSalim Yusuf
Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
N Engl J Med 358:1547-59. 2008..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
- Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertensionWilliam B White
Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 3940, USA
Hypertension 57:413-20. 2011..Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class...
- Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancerTakeo Kosaka
Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
Prostate 67:41-9. 2007..This study was then undertaken to investigate the effects of AT1R blockade using candesartan in prostate cancer (PCa)...
- Telmisartan: a different angiotensin II receptor blocker protecting a different population?M Burnier
Division of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
J Int Med Res 37:1662-79. 2009..A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients...
- Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationDanilo Fliser
Division of Nephrology, Department of Internal Medicine, Medical School Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
Circulation 110:1103-7. 2004....
- Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in ItalyGiovanni Corrao
Department of Statistics, Unit of Biostatistics and Epidemiology, University of Milano Bicocca, Milan, Italy
J Hypertens 26:819-24. 2008..To assess rates and determinants of treatment discontinuation of or changes in initial antihypertensive drug therapy in a large cohort of patients from Lombardia (Italy)...
- A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effectsMasahiro Fujino
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
Hypertens Res 33:1044-52. 2010..In conclusion, irbesartan induced greater beneficial effects than losartan due to small differences between their molecular structures, and these differential effects were both dependent on and independent of the AT₁ receptor...
- Combination therapy in hypertensionAlan H Gradman
The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania and Temple University School of Medicine, Philadelphia, PA 15224, USA
J Am Soc Hypertens 4:42-50. 2010..The advantages and disadvantages of single pill (fixed) drug combinations, and the implications of recent clinical trials involving specific combination strategies will also be discussed...
- A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine bindingJuan M Saavedra
Section on Pharmacology, National Institute of Mental Health, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
Neuropsychopharmacology 31:1123-34. 2006..We propose that AT1 receptor antagonists can be considered as compounds with possible therapeutic anti-stress and anti-anxiety properties...
- A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonistsMartin C Michel
Department of Clinical Development and Medical Affairs, Boehringer Ingelheim, 55216 Ingelheim, Germany
Pharmacol Rev 65:809-48. 2013..Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed...
- Reduction of proteinuria with angiotensin receptor blockersJan Galle
Department of Nephrology and Dialysis at Klinikum Lüdenscheid, Ludenscheid, Germany
Nat Clin Pract Cardiovasc Med 5:S36-43. 2008..These data support the proposition that blockade of the renin-angiotensin system beyond that required for maximum blood pressure reduction provides optimum renal protection...
- Telmisartan is a potent target for prevention and treatment in human prostate cancerKiyoaki Funao
Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545 8585, Japan
Oncol Rep 20:295-300. 2008..Telmisartan may mediate potent antiproliferative effects against PC cells through PPAR-gamma. Thus, Telmisartan is a potent target for prevention and treatment in PC...
- Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activationKoichi Yamamoto
Department of Geriatric Medicine, Osaka University Graduate School of Medicine, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
Hypertension 54:1353-9. 2009..It might be postulated that inhibition of AKT activation is a mechanism mediating the antiproliferative effects of telmisartan, including in cells lacking AT1 receptors or PPARgamma...
- Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist dockingPandian Sokkar
School of Chemistry, Madurai Kamaraj University, Madurai 625021, Tamil Nadu, India
J Mol Model 17:1565-77. 2011....
- High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cellsNaohiro Yano
Department of Pediatrics, Women and Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
Biochem J 423:129-43. 2009..These results suggest that high ambient glucose induces activation of AT-1R in an Ang II-independent manner to transactivate PI3K, resulting in proliferation and ECM accumulation in mesangial cells...
- The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospectivKazuyuki Shimada
Jichi Medical University School of Medicine, Shimotsuke, Japan
Hypertens Res 31:1903-11. 2008..However, further investigation is required to fully characterize the cardiovascular risks associated with masked HT among Japanese patients receiving treatment...
- Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trialAtsushi Hirohata
Sakakibara Heart Institute of Okayama, Okayama, Japan
J Am Coll Cardiol 55:976-82. 2010..The aim of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis...
- High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytesVivek P Singh
Division of Molecular Cardiology, Cardiovascular Research Institute, Texas A and M Health Science Center, College of Medicine, Temple, TX 76504, USA
Am J Physiol Heart Circ Physiol 293:H939-48. 2007..Significantly, NRVM synthesized and retained ANG II intracellularly, which redistributed to the nucleus under high-glucose conditions, suggesting a role for an intracrine mechanism in diabetic conditions...
- Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthaseChi Yung Yuen
Institute of Vascular Medicine, Li Ka Shing Institute of Health Sciences, School of Biomedical Sciences, Chinese University of Hong Kong, Shatin, N T, Hong Kong, China
Cardiovasc Res 90:122-9. 2011....
- I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospGuillaume Bobrie
Department of Hypertension, Hopital Europeen Georges Pompidou, Paris, France
Clin Ther 34:1705-19. 2012..Newer antihypertensive treatment combinations include fixed-dose combinations of an angiotensin receptor blocker and a calcium channel blocker...
- Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix productionVivek P Singh
Cardiovascular Research Institute, Texas A and M HSC, Temple, TX 76504, USA
Am J Physiol Heart Circ Physiol 294:H1675-84. 2008....
- Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trialDingliang L Zhu
Shanghai Ruijin Hospital, Shanghai Institute of Hypertension, 197 Ruijin 2nd Road, Shanghai, China
Clin Ther 34:1613-24. 2012..Patients with grade 2 or 3 hypertension may require high-dose combination therapy to achieve blood pressure (BP) targets in a timely manner...
- Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trialMarcello Disertori
Department of Cardiology, Santa Chiara Hospital, Trento, Italy
Am Heart J 162:382-9. 2011..In a consistent percentage of cases, AF recurrences are asymptomatic, thus making its clinical management difficult in relation to both therapeutic efficacy and thromboembolic risk...
- Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trialToshio Ogihara
Osaka University Graduate School of Medicine, Osaka, Japan
Hypertension 51:393-8. 2008..We disclosed that candesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlodipine...
- Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive ratsToru Dejima
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama 236 0004, Japan
J Hypertens 29:1919-29. 2011..In this study we examined whether the regulation of renal ATRAP expression is related to the development of salt-induced hypertension and renal injury as well as to the beneficial effects of AT1R blockade...
- Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytesTao Pang
Section on Pharmacology, Division of Intramural Research Programs, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
J Hypertens 30:87-96. 2012....
- Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activationShanna A Arnold
Division of Surgical Oncology, Department of Surgery and Pharmacology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
PLoS ONE 7:e31384. 2012....
- Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN studyJoel M Neutel
Orange County Research Center, Tustin, CA 92780, USA
J Clin Hypertens (Greenwich) 14:206-15. 2012..T/A SPCs were well tolerated...
- Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety studyLiyuan Ma
Department of Evidence Based Medicine, Cardiovascular Institute, Beijing, China
Am J Cardiovasc Drugs 12:137-42. 2012....
- The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analysesPeter Trenkwalder
Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Starnberg, Germany
J Hypertens Suppl 24:S107-14. 2006..Results in other subgroups were generally consistent with those in the entire SCOPE study population. In patients with slightly low cognitive function at baseline, the MMSE score declined less in the candesartan group...
- Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic ratsAkira Nishiyama
Department of Pharmacology, Kagawa University Medical School, 1750 1 Ikenobe, Miki cho, Kita gun, Kagawa 761 0793, Japan
J Pharmacol Exp Ther 332:1072-80. 2010Treatment with angiotensin II type 1 receptor blockers (ARBs) is the first-line therapy for hypertensive patients with diabetic nephropathy...
- A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazideMatthew R Weir
University of Maryland School of Medicine, Baltimore, MD, USA
J Clin Hypertens (Greenwich) 13:404-12. 2011....
- Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)Joachim Schrader
Department of Internal Medicine, St Josefs Hospital, Cloppenburg, Germany
Stroke 36:1218-26. 2005..In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality...
- Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose toleranceStefan Pscherer
Department of Nephrology and Diabetology, KlinikumTraunstein, Traunstein, Germany
Diabetes Care 33:914-9. 2010..The study investigated the effect of angiotensin receptor blockers (ARB) on glucose homeostasis and inflammatory parameters in patients with impaired glucose tolerance (IGT)...
- Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathySusumu Ogawa
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University School of Medicine, Sendai, Japan
Hypertens Res 30:325-34. 2007..Even among patients treated with an ACEI and/or ARB, lowering BP is important...
- Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosisNadine Nagy
Institut fur Pharmakologie, Universitatsklinikum Essen, Universitat Duisburg Essen, Hufelandstrasse 55, 45122, Essen, Germany
Basic Res Cardiol 105:29-38. 2010..Thus, biglycan is a pleiotropic target of telmisartan that might contribute to the anti-atherogenic effects of this AT1-antagonist...
- Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reductionN D Vaziri
Division of Nephrology and Hypertension, University of California, Irvine, CA, USA
J Pharmacol Exp Ther 323:85-93. 2007..Thus, the study demonstrated a link between up-regulation of Ang II/AT1r system and oxidative stress, inflammation, hypertension, and progression of renal disease in rats with renal mass reduction...
- Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failureIrving H Zucker
Dept of Cellular and Integrative Physiology, 985850 Nebraska Medical Center, Omaha, NE 68198 5850, USA
Am J Physiol Heart Circ Physiol 297:H1557-66. 2009..Finally, exercise training reduces both central oxidative stress and AT(1)R expression in animals with CHF. These data strongly suggest that multiple central and peripheral influences dynamically alter AT(1)R expression in CHF...
- Valsartan: more than a decade of experienceHenry R Black
New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York 10003, USA
Drugs 69:2393-414. 2009..The combination of valsartan/HCTZ was better tolerated than HCTZ alone. Valsartan is administered once daily for hypertension; doses are usually taken upon awakening. In patients with HF or MI, valsartan is administered twice daily...
- Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog modelsKeiji Kusumoto
Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka, Japan
Eur J Pharmacol 669:84-93. 2011..These results suggest that azilsartan medoxomil is a potent angiotensin II receptor blocker that has an attractive pharmacological profile as an antihypertensive agent...
- Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humansLionel Coltamai
Service of Nephrology and Hypertension Consultation, Department of Medicine, CHUV, Lausanne, Switzerland
J Hypertens 28:520-6. 2010....
- Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial studyThomas W Littlejohn
Piedmont Medical Research Associates, Winston Salem, NC 27103, USA
Postgrad Med 121:5-14. 2009..An angiotensin receptor blocker (ARB) plus a calcium channel blocker (CCB) seems particularly attractive for these difficult-to-control patients...
- Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal diseaseMaartje C J Slagman
Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands
Curr Opin Nephrol Hypertens 19:140-52. 2010..This review discusses the place of dual RAAS blockade in improving these outcomes...
- Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patientsToshihiro Hamada
Department of Cardiovascular Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
Am J Hypertens 21:1157-62. 2008..However, it is still unknown whether the inhibitory effect of losartan on URAT1 contributes to its uricosuric action in humans...
- Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai
Department of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 50:1959-66. 2007..We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients...
- Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarctionZamaneh Kassiri
Department of Physiology, University of Alberta, Edmonton, Canada
Circ Heart Fail 2:446-55. 2009..We hypothesized that ACE2 deficiency may compromise the cardiac response to myocardial infarction (MI)...
- Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetesKwan Yi Chu
Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories
Diabetes 55:367-74. 2006..Whether islet AT1R activation plays a role in the pathogenesis of human type 2 diabetes remains to be determined...
- Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failureMasayuki Shimano
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Heart Rhythm 5:451-9. 2008..There is evidence that pioglitazone improves ventricular remodeling in some experimental models...
- Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trialGennaro Cice
Second University of Naples, Naples, Italy
J Am Coll Cardiol 56:1701-8. 2010....
- Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive ratsKumiko Takemori
Department of Pathology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
Life Sci 77:2233-45. 2005..This may be due to the low concentration of plasma angiotensin II by continuous inhibition of RAS even after maturation...
- Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin IIYunzeng Zou
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
Nat Cell Biol 6:499-506. 2004..All of these events are inhibited by the AT1 receptor blocker candesartan. Thus, mechanical stress activates AT1 receptor independently of angiotensin II, and this activation can be inhibited by an inverse agonist of the AT1 receptor...
- In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studiesMami Ojima
Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka, Japan
J Pharmacol Exp Ther 336:801-8. 2011..Its tight receptor binding might be expected to produce potent and long-lasting antihypertensive effects in preclinical and clinical settings...
- Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implicationsJuan M Saavedra
Section on Pharmacology, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, 10 Center Drive, Building 10, Room 2D 57, Bethesda, MD 20892, USA
Psychoneuroendocrinology 36:1-18. 2011..Blockade of AT(1) receptors offers a novel and safe therapeutic approach for the treatment of illnesses of increasing prevalence and socioeconomic impact, such as mood disorders and neurodegenerative diseases of the brain...
- Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesisChristiane Ruster
Department of Internal Medicine III, Friedrich Schiller University, Erlanger Allee 101, D 07740 Jena, Germany
J Am Soc Nephrol 22:1189-99. 2011..A better understanding of the multiple morphogenic effects of Ang II may be necessary to develop better strategies to halt the progression of renal disease...
- Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney diseaseMarc Dilauro
Division of Nephrology, Departments of Medicine and Cellular and Molecular Medicine, The Ottawa Hospital, and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
Am J Physiol Renal Physiol 298:F1523-32. 2010..In contrast, ANG-(1-7) does not affect albuminuria after (5/6) Nx. We propose that endogenous ACE2 is renoprotective in CKD...
- Medical management of small abdominal aortic aneurysmsB Timothy Baxter
University of Nebraska Medical Center, Omaha, NE, USA
Circulation 117:1883-9. 2008..Additional studies are needed to clarify the potential role of doxycycline, roxithromycin, and statin therapy in the progression of aneurysmal disease...
- Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma systemMichael L Tuck
Department of Medicine, VA Medical Center, Sepulveda 111E, Building 200, Room 3430, North Hills, CA 91343, USA
Curr Hypertens Rep 7:240-3. 2005..The results imply that the ARB agent, telmisartan, could treat both the hemodynamic and metabolic aberrations seen in subjects with the metabolic syndrome, such as insulin resistance, glucose intolerance, and hypertension...
- Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injuryJun Li
Center for Cardiovascular Research Institute of Pharmacology and Toxicology, Charite University Medicine Berlin, Germany
FASEB J 19:617-9. 2005..Our data indicate that cerebral AT2 receptors exert neuroprotective actions in response to ischemia-induced neuronal injury, possibly by supporting neuronal survival and neurite outgrowth in peri-ischemic brain areas...
- The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetesEffie L Gillespie
School of Pharmacy, University of Connecticut, Storrs, USA
Diabetes Care 28:2261-6. 2005..Patients who utilize either an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes...
- Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout miceSven Wassmann
Klinik fur Innere Medizin III, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
Circulation 110:3062-7. 2004..Angiotensin II type 1 (AT1) receptor activation is potentially involved in the multifactorial pathogenesis of atherosclerosis...
- Circulating transforming growth factor-beta in Marfan syndromePeter Matt
602 Mason F Lord Bldg, Center Tower, Johns Hopkins University, Baltimore, MD 21239, USA
Circulation 120:526-32. 2009..We hypothesized that dysregulation of TGF-beta might be mirrored in circulating TGF-beta concentrations...
- Irbesartan in patients with atrial fibrillationSalim Yusuf
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
N Engl J Med 364:928-38. 2011..The risk of cardiovascular events among patients with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk...
- The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibitionSteven A Atlas
James J Peters VA Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468, USA
J Manag Care Pharm 13:9-20. 2007..Dysregulation of the RAAS plays an important role in the pathogenesis of cardiovascular and renal disorders...
- Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2bTrevor G Marshall
Autoimmunity Research Foundation, Thousand Oaks, California 91360, USA
Theor Biol Med Model 3:1. 2006....
- Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancerTakeo Kosaka
Department of Urology, Keio University School of Medicine, Shinjuku ku, Tokyo, Japan
Prostate 70:162-9. 2010..However, the downstream transcriptional factors induced by Ang II in prostate cancer cells have not been fully elucidated yet...
- Review: angiotensin II type 1 receptor blockers: class effects versus molecular effectsShin Ichiro Miura
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
J Renin Angiotensin Aldosterone Syst 12:1-7. 2011..This review focuses on the class effects versus molecular effects of ARBs from bench to bedside...
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialStevo Julius
University of Michigan, Ann Arbor, USA
Lancet 363:2022-31. 2004....
- Angiotensin II blockade and aortic-root dilation in Marfan's syndromeBenjamin S Brooke
McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
N Engl J Med 358:2787-95. 2008..We evaluated the clinical response to ARBs in pediatric patients with Marfan's syndrome who had severe aortic-root enlargement...
- Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic statesRonald D Cohn
McKusick Nathans Institute of Genetic Medicine, Baltimore, Maryland 21205, USA
Nat Med 13:204-10. 2007..Moreover, we show TGF-beta-induced failure of muscle regeneration and a similar therapeutic response in a dystrophin-deficient mouse model of Duchenne muscular dystrophy...
- Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonistsDavid V Erbe
Wyeth Research, Cambridge, MA 02140, USA
Vascul Pharmacol 45:154-62. 2006....
- PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectinRonald Clasen
Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Charite Campus Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
Hypertension 46:137-43. 2005..ARB-induced adiponectin stimulation is likely to be mediated via PPARgamma activation involving a post-transcriptional mechanism...
- Brain angiotensin II: new developments, unanswered questions and therapeutic opportunitiesJuan M Saavedra
Section on Pharmacology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, 10 Center Drive, Room 2D 57, Bethesda, Maryland 20892, USA
Cell Mol Neurobiol 25:485-512. 2005....
- Angiotensin receptors: a new role in cancer?Frederique Deshayes
Institut Cochin, CNRS UMR8104 INSERM U567, Departement de Biologie Cellulaire, 22 rue Mechain, 75014 Paris, France
Trends Endocrinol Metab 16:293-9. 2005..An overview of the major intracellular signaling pathways associated with AT1R and AT2R activation in cancer cells, as well as in endothelial and inflammatory cells, is presented here...
- Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive ratsMichiya Igase
Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
Am J Physiol Heart Circ Physiol 289:H1013-9. 2005....
- Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blockerEoin O'Brien
Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland
Hypertension 49:276-84. 2007....
- The obese patient with diabetes mellitus: from research targets to treatment optionsArya M Sharma
Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
Am J Med 119:S17-23. 2006..Clinical trials with telmisartan are currently investigating the effects of RAS blockade on insulin sensitivity in humans...
- Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptorShin Ichiro Miura
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
PLoS ONE 7:e37974. 2012..In addition, all of the experimental data were obtained with functional receptors in a native membrane environment (in situ)...
- Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI)G Uehara
Department of Internal Medicine, Takeda Clinic, Kanagawa, Japan
J Int Med Res 36:1094-102. 2008..We conclude that candesartan is a potentially useful therapy against arterial stiffness in hypertensive patients with type 2 diabetes mellitus...
- A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndromeWojciech Kosmala
Department of Cardiology, Wroclaw Medical University, Wroclaw, Poland
JACC Cardiovasc Imaging 4:1239-49. 2011....
- Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in SwitzerlandAndrew J Palmer
Center for Outcomes Research CORE, Binningen Basel, Switzerland
Swiss Med Wkly 136:346-52. 2006....
- Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan TrialYan Miao
Department of Clinical Pharmacology, University Medical Centre Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
Hypertension 58:2-7. 2011..These findings support the view that SUA may be a modifiable risk factor for renal disease...
- Angiotensin II Mediates Early Changes in Diabetic KidneyHelmy Siragy; Fiscal Year: 2007..The proposed studies will help understand the mechanisms that are involved in diabetic the development of new therapeutic modalities to prevent or slowdown the development ..
- AT2 Receptor Modulates Renal Angiotensin II LevelsHelmy Siragy; Fiscal Year: 2005..Data obtained from this proposal will lead to increased understanding of the pathophysiology of hypertension and development of novel therapies for its management. ..
- Oxidative Stress and Genetics of PrehypertensionShawna Nesbitt; Fiscal Year: 2004..abstract_text> ..
- MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITSThomas Giles; Fiscal Year: 2001..The exacerbation or prevention of EIH will be related to drug effects on the cell-signaling pathway. This research can define the cell-signaling pathway in EIH and provide new and novel approaches to treating EIH. ..
- ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEMCarlos Ferrario; Fiscal Year: 2004..The proposed research will uncover novel mechanisms of atherogenesis that may have significant impact in the development of new therapeutic modalities applicable to cardiovascular and blood vessel diseases. ..
- KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSIONTheodore Kurtz; Fiscal Year: 2003..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
- WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?Theodore Kurtz; Fiscal Year: 2003....
- AASK Cohort StudyGeorge Bakris; Fiscal Year: 2007..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
- ANG II AND IGF-1 INTERACTION IN CARDIOVASCULAR TISSUEJames Sowers; Fiscal Year: 2003..Thus, the proposed investigation will explore the role of PI3-kinase in mediating the cardiovascular interactions of AngII/IGF-1 after both short-term in vitro Ang II exposure and longer-term in vivo Ang II tissue excess. ..
- Estrogen Modulates Injury-Induced InflammationSuzanne Oparil; Fiscal Year: 2007..These fundamental mechanistic studies will enhance our understanding of the pathobiology of vascular disease, particularly as it occurs in aging women, and will provide the basis for development of novel therapeutic strategies. ..
- ADVENTITIAL RESPONSE TO VASCULAR INJURY: ESTROGENSuzanne Oparil; Fiscal Year: 2003..These fundamental mechanistic studies will establish more rational strategies for therapeutic intervention in vascular diseases, including the basis for future gene therapy. ..
- Novel Risk Factors for Chronic Kidney DiseaseRonald Klein; Fiscal Year: 2008..The new data may provide insights into the relative protective value of low levels of these markers on the incidence CKD in an aging population. [unreadable] [unreadable] [unreadable]..
- Multi-Ethnic Study of Atherosclerosis-Eye StudyRonald Klein; Fiscal Year: 2005..insights into the relative contribution of microvascular disease to the pathophysiology and natural history of subclinical and clinical cardiovascular disease, in representative populations of men and women of diverse ethnicities ..
- PAI-1 and The Vascular Toxicity of AldosteroneNancy Brown; Fiscal Year: 2005..This multi-disciplinary approach will generate new information regarding the role of aldosterone in vascular toxicity and, thus, improve our ability to prevent and treat cardiovascular disease. ..
- Identification of Serum Markers of Liver Fibrogenesis/ Fibrolysis by ProteomicsDetlef Schuppan; Fiscal Year: 2008..Adaptation to the human proteome and prospective validation shall allow noninvasive monitoring of fibrosis progression and regression in patients with liver diseases. [unreadable] [unreadable] [unreadable]..
- Microvascular - Macrovascular Disease in Type 2 DiabetesRonald Klein; Fiscal Year: 2005....
- Mouse Models for Celiac DiseaseDetlef Schuppan; Fiscal Year: 2007..g. by immunomodulatory cytokines or by cytokine antagonists. It is anticipated that the results will improve our understanding and management of cd and related autoimmune diseases. ..
- RAAS, Inflammation & Post-Operative Atrial FibrillationNancy Brown; Fiscal Year: 2009..abstract_text> ..
- African American Study of Kidney Disease and Hypertensi*Robert Toto; Fiscal Year: 2007..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
- Lipoproteins, HIV, and Antiretroviral Therapy in SMARTDaniel Duprez; Fiscal Year: 2008..This proposal will produce additional information that will enhance their disease-free survival rate. (End of Abstract) [unreadable] [unreadable] [unreadable]..
- Vanderbilt Mentored Clinical Research Scholar ProgramNancy Brown; Fiscal Year: 2006..The VCRS program will train successful new clinical investigators who will serve as leaders role in the post-genomic era. [unreadable] [unreadable] [unreadable]..
- Circumventricular Organs and Cardiovascular RegulationJOHN COLLISTER; Fiscal Year: 2007..The results of these studies will greatly enhance our understanding of the central effects of Angll at two specific brain regions, and how these interactions play a role in the long-term control of arterial pressure. ..
- Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory MonitoringMarsha Raebel; Fiscal Year: 2008..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
- WISCONSIN EPIDEMIOLOGICAL STUDY OF CARDIOVASCULAR DISEASRonald Klein; Fiscal Year: 2002....
- ANGII NEURAL INTERACTIONS IN CARDIOVASCULAR CONTROLJOHN COLLISTER; Fiscal Year: 2002..Upon completion, Dr. Collister will have fully developed into an independent investigator. ..
- HIGH RESOLUTION ECHOCARDIOGRAPHY SYSTEMMichael Zile; Fiscal Year: 2001..This will foster interdisciplinary investigation, support NIH-funded investigators and trainees, and enhance the competitiveness of MUSC investigators. ..
- RETINAL ARTERIOLAR ABNORMALITIES AND CV MORTALITYRonald Klein; Fiscal Year: 2002..Data from this study will improve the understanding of the association between microvascular characteristics and cardiovascular mortality. ..
- Retinal Microvascular Characteristics/Vascular DisordersRonald Klein; Fiscal Year: 2003..abstract_text> ..
- TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCHRobert Toto; Fiscal Year: 2004..The proposed program will provide young physicians and scientists with the skills needed to conduct clinical investigations and to compete for federal and non-federal research funding. ..
- Improving Outcomes in Diabetic NephropathyRobert Toto; Fiscal Year: 2008..the renin-angiotensin-aldosteronesystem withangiotensin convertingenzyme inhibitors(ACEIs) or angiotensin II type 1 receptor blockers(ARBs)...
- Genetics of Chronic Kidney DiseaseStephen T Turner; Fiscal Year: 2010..abstract_text> ..
- ANGIOTENSIN II AND BRADYKININ IN CARDIAC HYPERTROPHYLOUIS DELL ITALIA; Fiscal Year: 2007..These studies will uncover new mechanistic insights and therapeutic strategies for VO. ..
- Atrial Fibrillation: Incidence, Risk Factors, and GeneticsSUSAN HECKBERT; Fiscal Year: 2010..The ultimate goal of this research is to increase knowledge about AF risk factors and prognosis and to enhance prevention efforts and improve care for patients with AF. ..
- Natriuretic mechanisms of AT2 receptorsROBERT MUNSON CAREY; Fiscal Year: 2010..This application will increase our understanding of the mechanisms whereby the kidney renin-angiotensin system regulates salt and water excretion, suggesting new molecular targets for the treatment and prevention of hypertension. ..
- Renal medullary COX-2 in blood pressure controlTianxin Yang; Fiscal Year: 2008..The information resulted from these studies will provide new insight into the molecular mechanism responsible for long-term control of arterial blood pressure. ..
- Impact of Medicaid Prescription Copayments in Patients with SchizophreniaJalpa Doshi; Fiscal Year: 2009..The findings of our study will help inform policymakers about the intended and unintended consequences of prescription copayments in Medicaid patients with schizophrenia. ..
- UW Multidisciplinary Clinical Research Training (RMI)Jeffrey Probstfield; Fiscal Year: 2007..unreadable] [unreadable]..
- PRESSURE NATRIURESIS MEDIATED BY EXTRACELLULAR cGMPRobert Carey; Fiscal Year: 2009..Proof of the specific aims will identify and characterize a novel role of extracellular Rl cGMP and provide a potential therapeutic target for hypertension and other disease states associated with sodium retention. ..
- The Renin-Angiotensin System, Inflammation and Radiation-induced Brain InjuryMichael E Robbins; Fiscal Year: 2010....
- Salsalate: A Diabetes Treatment for Carbonyl, Oxidative & Nitrosative StressJOSHUA ISRAEL BARZILAY; Fiscal Year: 2010..If effective, this treatment could reduce the risk of heart attacks and strokes that frequently occur in people with diabetes. ..
- PATHOPHYSIOLOGY OF DIABETIC NEPHROPATHYSharon Anderson; Fiscal Year: 2007..abstract_text> ..
- Human monoclonal antibody therapy for HUSHoward Trachtman; Fiscal Year: 2004..abstract_text> ..
- Folic Acid Intake and Risk of HypertensionJohn Forman; Fiscal Year: 2004..Subsequently, the risk of hypertension will be analyzed in > 2000 men and women genotyped for eNOS, and > 7000 men and women genotyped for MTHFR. Interaction with folate will be analyzed. ..
- Dysregulation of AT, receptor in Transgenic RatsMICHELLE CLARK; Fiscal Year: 2004..abstract_text> ..
- Renal Microcirculatory and Tubular DynamicsJoey Granger; Fiscal Year: 2004....
- Circulatory Dysfunction in Chronic Fatigue SyndromeJulian Stewart; Fiscal Year: 2004....
- Molecular Modulation of Cardiac Na+ Channel FunctionKatherine Murray; Fiscal Year: 2004..abstract_text> ..
- Fatty Acids, Angiotensin and Oxidative StressBrent Egan; Fiscal Year: 2004..We believe the information generated by the proposed studies has the potential for elucidating biological mechanisms underlying obesity-associated hypertension and the potential for dietary anti-oxidants to modulate BP. ..
- THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMENPaul Ridker; Fiscal Year: 2002....
- Intercellular Signaling in Obstructive NephropathyROBERT CHEVALIER; Fiscal Year: 2005..This will lead to improved outcomes in adulthood. ..
- Regulation of minerals and fluids excretion in vitamin DYan Chun Li; Fiscal Year: 2005..The third goal is to study the effect of VDR inactivation on ANP expression and sodium and body fluid balance, in order to test in vivo, the hypothesis that 1,25(OH)2D3 negatively regulates ANP expression. ..
- GENETIC EPIDEMIOLOGY OF RESPONSES TO ANTIHYPERTENSIVESStephen Turner; Fiscal Year: 2006....
- Mechanisms of Oxidant Signaling in Post-MI RemodelingWilson Colucci; Fiscal Year: 2007..These studies will provide new understanding of the mechanisms of oxidant signaling in myocardial remodeling post-MI, and will therefore have direct relevance to a common cause of heart failure in patients. [unreadable] [unreadable]..
- Cardiovascular Effects of lyengar YogaRaymond Townsend; Fiscal Year: 2006..unreadable] [unreadable]..
- Interaction of COX-2 and nNOS in renin secretionTianxin Yang; Fiscal Year: 2006....
- Life Cycle Effects of Health Insurance on Elderly HealthJalpa Doshi; Fiscal Year: 2006..We will use these estimates to simulate the effect of changes in the age of Medicare eligibility on health, medical service use and Medicare expenditure. ..
- Beta3-Adrenergic Receptor & Progression to Heart FailureChe Ping Cheng; Fiscal Year: 2006..Thus, provide valuable new insight into the mechanism of the progression of functional impairment in CHF, and may assist in specifically targeting therapy for CHF. ..
- Renal & Cellular Studies in Type 1 Diabetic PatientsS Mauer; Fiscal Year: 2007..These studies will provide markers and predictors of DN risk, determine if these are genetically regulated or dependent on prior exposure to D, and identify DN pathogenetic pathways. ..
- POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPYWanpen Vongpatanasin; Fiscal Year: 2006..The long-term goal of her work would be the discovery the most effective estrogen preparation that can prevent or treat hypertension in women after menopause. ..
- UW CLINICAL RESEARCH TRAINING PROGRAMJeffrey Probstfield; Fiscal Year: 2004..abstract_text> ..
- ROS and NO interaction in the PVN during hypertension?CARRIE NORTHCOTT; Fiscal Year: 2006..unreadable] [unreadable]..
- CELL GROWTH, NA/H EXCHANGE, AND CYCLINS IN IDDM PATIENDaniel Batlle; Fiscal Year: 2002....